Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Cocrystal PharmaCocrystal Pharma is a clinical-stage biotechnology company specializing in the discovery and development of novel antiviral therapeutics for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, norovirus, and other respiratory viruses. The company leverages structure-based drug discovery technology and expertise in structural biology to design direct viral replication inhibitors with broad-spectrum activity. Its pipeline includes candidates in preclinical and clinical development, addressing unmet needs in antiviral medicine.
Cocrystal Pharma is a clinical-stage biotechnology company specializing in the discovery and development of novel antiviral therapeutics for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, norovirus, and other respiratory viruses. The company leverages structure-based drug discovery technology and expertise in structural biology to design direct viral replication inhibitors with broad-spectrum activity. Its pipeline includes candidates in preclinical and clinical development, addressing unmet needs in antiviral medicine.
Publication Number
US-12649715-B2
Publication Date
2026-06-09
Expiration Date
Abstract
Methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and of treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound of Table A, or a pharmaceutically acceptable salt thereof.
Core Innovation
The invention relates to compounds as recited in Table A, or pharmaceutically acceptable salts thereof, for antiviral use. The disclosed compounds are specific chemical entities identified in Table A, and the approach defines reduction of viral titer and inhibition of viral replication as therapeutic and prophylactic outcomes.
The disclosed structures include a sulfonylated scaffold bearing carboxamide/amide functionality and a bicyclic core, with variations defined on a left aromatic/heteroaryl portion and stereochemistry on a right-hand chiral ring system. The disclosure further describes structural alternatives for moiety Z, including alkylene-OH derivatives, SO3H-substituted alkylene-OH, aldehyde, heterocycles, and CONRARB, together with defined sulfonyl-related motifs.
The disclosure further covers pharmaceutical composition embodiments that include the Table A compound or pharmaceutically acceptable salt together with additional pharmaceutical composition elements, including a pharmaceutically acceptable excipient. It further includes the use of the compound for manufacturing a medicament for treating norovirus/coronavirus infection and describes intranasal, pulmonary, and other delivery forms, including intranasal aerosol and pulmonary delivery concepts.
Claims Coverage
The document contains one independent claim directed to a specific compound identified in Table A, or a pharmaceutically acceptable salt thereof, and a dependent claim refining this into a pharmaceutical formulation with a pharmaceutically acceptable excipient. Overall, the claim set centers on two inventive features: compound identity by Table A and formulation composition with an excipient.
Table A compound or pharmaceutically acceptable salt
A compound as recited in Table A, or a pharmaceutically acceptable salt thereof.
Pharmaceutical formulation with pharmaceutically acceptable excipient
A pharmaceutical formulation that includes the compound or its salt together with a pharmaceutically acceptable excipient.
The claim coverage focuses on a specifically identified Table A compound and a formulation embodiment comprising that compound or its salt with a pharmaceutically acceptable excipient.
Stated Advantages
Inhibits norovirus and coronavirus replication by reducing viral amount, including viral titer.
Used for treating or preventing norovirus/coronavirus infection.
Reduces norovirus replication.
Reduces coronavirus replication.
Reduces viral titer.
Documented Applications
Inhibiting norovirus and coronavirus replication by administering a safe and effective amount of Table A compounds or pharmaceutically acceptable salts to a biological sample/patient.
Treatment or prevention of norovirus/coronavirus infection.
Use for manufacturing a medicament for treating norovirus/coronavirus infection.
Therapeutic and prophylactic use in patients for inhibiting norovirus/coronavirus replication and reducing viral titer.
Pulmonary (inhalation) delivery concepts within pharmaceutical compositions.
Interested in licensing this patent?